Oculis Trial Shows Potential for Optical Neuroprotective Therapy

Exec Edge

01-07

By Karen Roman

Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis.

Oculis also said it received the Investigational New Drug application clearance from the FDA.

“We are excited to further advance OCS-05’s development in acute optic neuritis, while actively exploring its potential in additional neuro-ophthalmic indications with the aim to deliver a first-in-class neuroprotective treatment option to patients,” said Riad Sherif, Oculis’ CEO.

Contact:

Exec Edge

Editor@executives-edge.com

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2501296629"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501296629\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2501296629?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 06:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2501296629","market":"us","top_or_hot":-1,"title":"Oculis Trial Shows Potential for Optical Neuroprotective Therapy","media":"Exec Edge","content":"<html><body><p><img height=\"642\" src=\"https://s1.yimg.com/uu/api/res/1.2/jw5indjOBvrJRftkXBFzUw--/cT03NTthcHBpZD15dmlkZW9mZWVkczs-/https://media.zenfs.com/en/exec_edge_220/a613ca440c02807ea06bbed3db5751bc\" width=\"1536\"/></p>\n<p>By Karen Roman</p>\n<p><a href=\"https://laohu8.com/S/OCS\">Oculis</a> Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis.</p>\n<p>Oculis also said it received the Investigational New Drug application clearance from the FDA.</p>\n<p>“We are excited to further advance OCS-05’s development in acute optic neuritis, while actively exploring its potential in additional neuro-ophthalmic indications with the aim to deliver a first-in-class neuroprotective treatment option to patients,” said Riad Sherif, Oculis’ CEO.</p>\n<p>Contact:</p>\n<div>\nExec Edge\n</div>\n<div>\n<p>Editor@executives-edge.com</p>\n</div></body></html>","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oculis Trial Shows Potential for Optical Neuroprotective Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOculis Trial Shows Potential for Optical Neuroprotective Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-07 06:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/oculis-trial-shows-potential-optical-223042372.html><strong>Exec Edge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Karen Roman\nOculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis.\n...</p>\n\n<a href=\"https://finance.yahoo.com/news/oculis-trial-shows-potential-optical-223042372.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OCS","symbol_name":"Oculis","start_time":0,"source_url":"https://finance.yahoo.com/news/oculis-trial-shows-potential-optical-223042372.html","article_id":"2501296629","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501296629","pubTimestamp":1736202642,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Oculis Holding AG  said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis.Oculis also said it received the Investigational New Drug application clearance from the FDA.“We are excited to further advance OCS-05’s development in acute optic neuritis, while actively exploring its potential in additional neuro-ophthalmic indications with the aim to deliver a first-in-class neuroprotective treatment option to patients,” saidRiad Sherif, Oculis’ CEO.","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"OCS":"Oculis","BK4007":"制药","OCSAW":"OCULIS HOLDING AG C/WTS 02/03/2028 (TO PUR ORD)","OCC":"Optical Cable Corporation","BK4020":"通信设备"},"translate_title":"Oculis试验显示视神经保护疗法的潜力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OCC":1,"OCS":1,"OCSAW":0.9},"content_text":"By Karen Roman\nOculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of safety and efficacy, highlighting its potential to treat acute optic neuritis.\nOculis also said it received the Investigational New Drug application clearance from the FDA.\n“We are excited to further advance OCS-05’s development in acute optic neuritis, while actively exploring its potential in additional neuro-ophthalmic indications with the aim to deliver a first-in-class neuroprotective treatment option to patients,” said Riad Sherif, Oculis’ CEO.\nContact:\n\nExec Edge\n\n\nEditor@executives-edge.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}